Investing
GSK says FDA extends review period for experimental drug momelotinib
© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis.
Momelotinib is not currently approved in any market.
Read the full article here
-
Personal Finance6 days ago
Top personal finance New Year's resolutions for 2025
-
Passive Income4 days ago
Join the Highest-Growing Industry in 2025 With This $60 Cybersecurity E-Learning Bundle
-
Passive Income7 days ago
Why Emotional Intelligence Is the Key to High-Impact Leadership
-
Side Hustles7 days ago
3 Key Ways to Train Your Franchisees
-
Make Money7 days ago
How the Rich Build Wealth That Lasts: 8 Tactics
-
Side Hustles7 days ago
12 Big Ideas From Business Books Published In 2024
-
Investing7 days ago
Work Better from Anywhere with This Portable Touchscreen Monitor
-
Passive Income2 days ago
Sending A Last-Minute Marketing Email? Follow This 7-Step Checklist to Avoid Making These Costly Mistakes